Should the proton‑pump inhibitor be discontinued before repeating a Bravo wireless pH study to accurately assess acid reflux?

Should PPI Be Discontinued Before Repeating Bravo pH Study?

Yes, the PPI must be discontinued for at least 7 days before repeating a Bravo wireless pH study to accurately assess acid reflux, even if the initial study was performed on PPI. Testing off PPI is essential to establish whether true pathological acid reflux exists and to maximize diagnostic accuracy 1.

Why Testing Off PPI Is Critical

The British Society of Gastroenterology guidelines explicitly state that in patients with symptoms suspected to be due to GERD but not responding to twice-daily PPIs who require wireless pH monitoring, the study should always be performed off PPIs 1. This recommendation is based on moderate-quality evidence with strong consensus.

Key Diagnostic Considerations

Testing on PPI severely limits diagnostic yield:

• Only 3.4% of patients tested on PPI show both abnormal acid exposure AND symptom-reflux association, compared to 30.4% when tested off PPI 1
• Very few patients (<4%) demonstrate persistent abnormal acid exposure on twice-daily PPIs 1
• The combination needed to confidently diagnose GERD—excess acid exposure plus symptom association—is nearly 10 times less common when testing on acid suppression 1

Recent clinical trial data strongly support this approach: patients with no evidence of abnormal esophageal acid exposure (AET >4.0%) in the first 7 days after PPI withdrawal are much more likely to successfully discontinue PPIs long-term 2, 3.

Practical Protocol for Repeat Testing

Medication Withdrawal Timeline

• Stop PPIs for 7 days minimum before the Bravo study 1
• Stop H2-receptor antagonists for 3 days 1
• Avoid antacids on the day of testing 1

Managing Withdrawal Symptoms

Expect rebound acid hypersecretion (RAHS):

• Parietal cell hyperplasia can persist for 8 weeks after PPI withdrawal, though typically regresses by 6 months 2
• Patients off PPIs for exactly 7 days have higher likelihood of symptom worsening compared to those off for >7 days (68.9% vs 41.2%, p=0.042) 4
• This acute symptom worsening may actually enhance diagnostic accuracy by unmasking true reflux 4

Symptom management during withdrawal:

• Use H2-receptor antagonists as needed for breakthrough symptoms 2
• Over-the-counter antacids for temporary relief 2
• Avoid resuming continuous PPI therapy 2

Optimal Study Duration and Analysis

96-hour monitoring is superior to 48-hour monitoring:

• Prognostic performance significantly declines when assessing only the first 48 hours (AUC 0.63 for 96 hours vs 0.57 for 48 hours, p=0.01) 5
• AET is significantly higher on day 1 compared to subsequent days 5
• Day-to-day variability in acid exposure is substantial 1

Use "average" analysis rather than "worst day":

• "Average" analysis across all recorded days provides 94.8% specificity versus 84.5% for "worst day" analysis 1
• This reduces false positives from isolated or brief alterations in acid exposure 1

When On-PPI Testing Might Be Considered

The only scenario where on-PPI pH-impedance monitoring has value is in patients with PROVEN GERD (from prior endoscopy or off-PPI testing) who remain symptomatic on twice-daily PPIs 1, 6. This approach:

• Assesses whether PPI dose is adequate
• Identifies persistent acid or non-acid reflux
• Distinguishes refractory GERD from functional heartburn

However, this does not apply to your patient's situation of repeating a Bravo study. Since the goal is to accurately assess whether pathological acid reflux exists, off-PPI testing is mandatory 1.

Critical Pitfall to Avoid

Do not interpret symptom worsening during the 7-day PPI withdrawal as automatic indication to resume PPIs or cancel testing. This rebound phenomenon is expected and actually correlates with acid reflux severity on subsequent Bravo testing 4. Symptom exacerbation following PPI cessation for at least 7 days correlated with abnormal acid exposure (59.6% with confirmed GERD reported worsening vs 50% without GERD, p=0.043) 4.

The diagnostic threshold of AET >4.0% performs best in predicting true PPI requirement (odds ratio 2.9, p=0.006) 5, 3, and this can only be accurately assessed off acid suppression.